Phathom Pharmaceuticals vs Syndax Pharmaceuticals
Phathom Pharmaceuticals reported revenue of $175 million in fiscal 2025, about the same as Syndax Pharmaceuticals' $172 million in fiscal 2025. Phathom Pharmaceuticals' revenue grew 216.9% in its latest year, and Syndax Pharmaceuticals' grew 627.8%. Phathom Pharmaceuticals had an operating margin of -91.4%, against -158.4% at Syndax Pharmaceuticals. Free cash flow was −$167 million at Phathom Pharmaceuticals and −$323 million at Syndax Pharmaceuticals.
Side by side
| Phathom Pharmaceuticals | Syndax Pharmaceuticals | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $175M | $172M |
| Revenue growth | 216.9% | 627.8% |
| Revenue growth a year, last 5 years | — | 158.3% |
| Gross margin | 87.1% | — |
| Operating margin | −91.4% | −158.4% |
| Net margin | −126.3% | −165.6% |
| Free cash flow | −$167M | −$323M |
| Free cash flow margin | −95.4% | −187.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 15.4% | 1.2% |
| Last close | $5.08 | $9.13 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | sold $2.7 million |
| Piotroski F-score | 4 of 9 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Phathom PharmaceuticalsSyndax Pharmaceuticals
Operating margin
Percent of revenue
Phathom PharmaceuticalsSyndax Pharmaceuticals
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Phathom PharmaceuticalsSyndax Pharmaceuticals
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Phathom Pharmaceuticals and Syndax Pharmaceuticals pages.